Bladder Cancer | Topics

A recent study published in Science evaluated DNA changes in healthy and disease-laden bladder tissue, finding that cancer-driving mutations are common in healthy bladder tissue.

Combination treatment with tremelimumab and durvalumab was found to be well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who are not eligible for cisplatin-based chemotherapy.

“This is the first trial to report objective responses in patients with advanced urothelial cancer who had previously received immunotherapy but were ineligible for cisplatin in this setting due to inadequate kidney function or other conditions,” Roger Dansey, MD, said in a press release.